Business Wire

COLOPL Group Company Brilliantcrypto Inc., Reveals “Brilliantcrypto,” The Blockchain Game Which Generates Economic Value in The Metaverse With Digital World Gemstones

25.7.2023 08:00:00 EEST | Business Wire | Press release

Share

The wholly owned subsidiary of COLOPL, Inc. (HQ: Minato City Tokyo; CEO: Takashi Miyamoto), Brilliantcrypto, Inc. (HQ: Minato City Tokyo; CEO: Naruatsu Baba), announced its new blockchain game “Brilliantcrypto,” which introduces the new “Proof of Gaming” concept at the global Web3 conference “WebX” (held on 25/07/2023).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230724611315/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

New blockchain game "Brilliantcrypto" (Graphic: Business Wire)

Game Overview
Brilliantcrypto is a blockchain game where players around the world become miners and excavate the mines with the aim of finding gemstones and tokens. Users buy pickaxes in the in-game marketplace, and use items like the “detector” while carrying out mining. By mining, players can obtain tokens and gemstones, and there will be the possibility to bring the gemstones, which can turn into NFTs, into many different metaverse worlds. There will also be the possibility to buy and sell the gemstones, as well as use them.

What is “Proof of Gaming”?
Simply put, “Proof of Gaming” is the game model version of “Proof of Work,” which is Bitcoin’s consensus algorithm.
In Bitcoin, mining is carried out in the form of a tremendous amount of hash calculations, which in turn guarantees value on the blockchain. Similarly, in Brilliantcrypto, mining will be carried out in the form of people throughout the world playing the game, which will guarantee the value of gemstones in the digital world.

Generating Economic Value In the Metaverse with “Proof of Gaming”
The metaverse is currently being developed, and we believe that one reason that could be given for it not fully catching on yet is that there is currently no “economic value.” If the value of digital world gemstones is guaranteed by “Proof of Gaming,” it becomes possible to use them not only in-game, but also in many different metaverse worlds, and so becomes possible to exchange them and use them. Therefore, the more exchanges begin to take place, the more the demand for gemstones with value will grow, and the more people from around the world will gather to play the game. We believe that through this cycle, “Proof of Gaming” will be activated further and as a result, true economic value will be generated in the metaverse.

Realizing Sustainable Play-to-Earn
In recent years, “play-to-earn,” which made it possible to earn money while playing games using a combination of blockchain technology and cryptocurrency, has been gathering global attention.
On the other hand, there has existed a sustainability issue with play-to-earn, as the system only allows individual, early adopters to actually make a profit. Through guaranteeing the value of digital world gemstones with Brilliantcrypto’s “Proof of Gaming” model, societal value will be generated and brought out into the world. That is why we believe sustainable play-to-earn can finally be made a reality.

About the Closed Beta Test
We will carry out a closed beta test before the official service launch.
Therefore, from today until Monday 08/08/2023 05:59 (UTC), we are accepting applications to participate in the beta.

Closed Beta Details
- Application Period: Tues. 25/07/2023 05:00 〜 Tues. 08/08/2023 05:59 (UTC)
- Amount of spots: Limited availability expected
- Beta Test Period:

1st Test: Tues. 15/08/2023 06:00 - Tues. 22/08/2023 05:59 (UTC)
2nd Test: Tues. 12/09/2023 06:00 - Tues. 19/09/2023 05:59 (UTC)
3rd Test: Tues. 10/10/2023 06:00 - Tues. 17/10/2023 05:59 (UTC)

- Clear Reward (1): Win ¥5000 worth of ETH (receivable by all who clear)
- Clear Reward (2): Enter a lottery, where 6 lucky players will win 2 VIP tickets to watch PSG play in France, in the tournament that decides the top European football team (return flight tickets included).

Closed Beta Application Page
https://beta-user-registration.brilliantcrypto.net

Game Website
https://brilliantcrypto.net

Social Media
- Twitter https://twitter.com/Brypto_Official
- Discord https://discord.gg/x23GWNu73B
- Youtube https://www.youtube.com/@Brilliantcrypto

Company Name: Brilliantcrypto, Inc.
Headquarters: Tokyo, Minato City, Akasaka 9-7-2, 5F & 6F Midtown East
Founded: 2022/11/09
Executive Director: Naruatsu Baba

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Point of Contact regardings inquiries from the media on this release
Brilliantcrypto PR Representative: Hugo Church, Naoki Nose, Yasuhiro Noguchi
Mail:press.contact@brilliantcrypto.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye